Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Appoints Sigma-Aldrich as Distributor of Duolink

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Olink Bioscience will continue to develop the protein biomarker market.

Olink Bioscience has announced the appointment of Sigma® Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, as distributor of the Duolink® In Situ product line in nearly all geographies worldwide for the research market.

The agreement will expand the market for Duolink In Situ by leveraging the industry-leading marketing, sales, support and distribution power of Sigma® Life Science.

“We believe our agreement will build awareness and develop the market for Duolink In Situ through the global sales and support organization that serves our growing customer base locally ”said Simon Fredriksson, CEO and President of Olink Bioscience.

Fredriksson continued, “The Sigma® Life Science product range for Cell Biology is extensive and a perfect context for customers interested in Duolink In Situ.”

“Duolink In Situ is a powerful addition to our portfolio of Proteomics products and will be readily available through the sigma-aldrich.com website", said Josef Zihlmann, Vice President, Marketing, Sigma Life Science.

Zihlmann continued, "The ability to visualize protein-protein interactions in unmodified cells under endogenous expression is a fundamental advance, and can provide enhanced insight into basic biology, disease-relevant signaling pathways, and potential therapeutic compounds that can manipulate those pathways”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New European Consortium to Boost our Understanding of IBD
A multi-modal integrated biomarker study Consortium to increase diagnostic precision in detection of the diseases.
Thursday, May 23, 2013
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!